AHFS® DRUG INFORMATION® 2021™

Free access

List Price: $440.00

Member Price: $360.00

Page Count: 3504

AHFS Drug Information® 2021 contains the most trustworthy drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. Benefits that are unique to AHFS® DI® include: 

  • The only print compendium designated by the U.S. Congress 
  • The only compendium published by a professional and scientific society 
  • The only reference that has been trusted by pharmacists and other healthcare professionals for over 60 years

Learn more about related resources, electronic only monographs, and the AHFS Clinical Drug Information App here.

AHFS® Drug Information® 2021 Edition is not available as an eBook. The front matter is available for all to see below. ASHP has an online application called AHFS® Clinical Drug Information™ available for purchase. For more information, please visit the site here or contact Customer Relations here.

AHFS Drug Information® 2021 contains the most trustworthy drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Updates in the 2021 edition include:

  • Drug information for COVID-19-related treatments, including use of antiviral agents such as remdesivir and lopinavir/ritonavir, SARS-CoV-2-specific monoclonal antibodies (e.g., bamlanivimab), as well as use of supporting agents such as corticosteroids, immune globulin, nitric oxide, and tocilizumab
  • Updated information on drugs commonly used for ICU sedation in critically ill patients with COVID-19, including propofol, dexmedetomidine, and midazolam and alternative drugs such as ketamine considered in potential drug shortage situations
  • Latest oncology therapies for the treatment of cancers associated with activating gene mutations and oncogenic gene fusions
  • Breakthroughs in oncology approved under the FDA's accelerated approval program
  • New information on non-oncology off-label uses

For a complete list of 2021 updates: click here.

Published by Authority of the Board of the AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS®
American Hospital Formulary Service®

 

EDITORIAL STAFF

Vice President, Publishing Office: Daniel J. Cobaugh, PharmD, DABAT, FAACT

Senior Associate Editor: Jane Miller, PharmD

Associate Editors: Natalie A. Mendham, PharmD

Assistant Editors: Joan D. Heydorn, BS, and Shingyee Cindy Huang, PharmD

Oncology Specialist Assistant Editor: Lily L. Leu, PharmD, BCOP

Assistant Editor for Injectables: Lisa M. Kohoutek, PharmD, BCPS

Senior Drug Information Analyst: Natalie C. Rosanelli, PharmD

Director of Clinical Informatics: Seth A. Strawbridge, PharmD

Project Manager: Elizabeth P. Shannon, BS

Editorial Coordinator: Allie Berry, MS

Contributing Editors: Susan K. Braun, BS Pharm, and Olin H. Welsh, Jr., PharmD

Contributors: Rachel L. Feinstein, PharmD, Lindsey R. Harper, PharmD, and Linda Bedford Arcuri, PharmD

"This book succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field. 

This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners. The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well." 

Melissa M. Potts, BS, PharmD, 2020